Pulmonary manifestations in systemic connective tissue diseases
From WikiLectures
Systemic connective tissue diseases are autoimmune diseases with multiorgan impairment due to vasculitis; frequent arthritis, muscle and skin damage. The onset of fibrosing alveolitis is a response to immunocomplexes deposited in the pulmonary capillaries. The treatment is corticotherapy.[1]
- Intersticial damage in 1.5 to 4.5%;
- clinically and histologically identical to KFA;
- prognosis: unfavorable in case of pulmonary changes;
- therapy: glucocorticoids + immunosuppressants.[1]
- Pulmonary impairment in 50 to 60%: most often pleurisy, ILD, rarely acute pneumonia;
- X-RAY: reticulonodular shadows with max. impairment of the lower lung fields;
- therapy: corticoids + penicillamine/cyclophosphamide;
- survival 10 to 14 years (cause of death renal failure, endarteritis or secondary pneumonia).[1]
- Scleroderma (progressive systemic sclerosis)
- ILD in up to 80% of patients [1]
Links[edit | edit source]
Related articles[edit | edit source]
- Chronic lung diseases • Interstitial lung processes
- Rheumatoid arthritis • Systemic lupus erythematosus • Scleroderma • Sjorgen's syndrome
Source[edit | edit source]
- CHILD, P., et al. Internal Medicine. 2nd edition. Prague: Galén, 2007. ISBN 978-80-7262-496-6 .
